Literature DB >> 31934588

Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer.

Andreas Minh Luu1, Philipp Hoehn1, Sina Rabea Vogel1, Anke Reinacher-Schick2, Johanna Munding3, Waldemar Uhl1, Chris Braumann1.   

Abstract

INTRODUCTION: Pancreatic cancer is a lethal disease and often asymptomatic. Therefore, it is most often diagnosed at an advanced stage. The standard approach in a metastasized tumor stage is palliative chemotherapy. However, the prognosis remains extremely poor. CASE REPORT: We present the case of a patient who was diagnosed with a cancer of the head of the pancreas with hepatic metastases. After receiving palliative intended chemotherapy with the FOLFIRINOX regimen, staging computed tomography revealed the disappearance of the liver metastases and local resectability of the pancreatic head tumor. The patient underwent an uneventful Whipple's procedure. Surprisingly, pathohistological investigation revealed a complete pathological response.
CONCLUSION: Pathological complete response after FOLFIRINOX treatment in hepatic metastasized pancreatic cancer is extremely rare. It enables surgical resection and increases the survival rate significantly.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  FOLFIRINOX; Hepatic metastases; Pancreatic cancer; Pathologic complete response; ypT0

Year:  2019        PMID: 31934588      PMCID: PMC6944898          DOI: 10.1159/000497827

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  19 in total

Review 1.  Pancreatic adenocarcinoma.

Authors:  Giles Bond-Smith; Neal Banga; Toby M Hammond; Charles J Imber
Journal:  BMJ       Date:  2012-05-16

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Authors:  Sing Yu Moorcraft; Khurum Khan; Clare Peckitt; David Watkins; Sheela Rao; David Cunningham; Ian Chau
Journal:  Clin Colorectal Cancer       Date:  2014-09-21       Impact factor: 4.481

4.  Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Authors:  Eric A Mellon; Sarah E Hoffe; Gregory M Springett; Jessica M Frakes; Tobin J Strom; Pamela J Hodul; Mokenge P Malafa; Michael D Chuong; Ravi Shridhar
Journal:  Acta Oncol       Date:  2015-03-03       Impact factor: 4.089

Review 5.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

6.  Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.

Authors:  Ingo Hartlapp; Justus Müller; Werner Kenn; Ulrich Steger; Christoph Isbert; Michael Scheurlen; Christoph-Thomas Germer; Hermann Einsele; Volker Kunzmann
Journal:  Onkologie       Date:  2013-02-25

7.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

8.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

Authors:  Matthew H G Katz; Peter W T Pisters; Douglas B Evans; Charlotte C Sun; Jeffrey E Lee; Jason B Fleming; J Nicolas Vauthey; Eddie K Abdalla; Christopher H Crane; Robert A Wolff; Gauri R Varadhachary; Rosa F Hwang
Journal:  J Am Coll Surg       Date:  2008-03-17       Impact factor: 6.113

9.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick; Joshua T Byers; Cheryl Meguid; Csaba Gajdos; Martin D McCarter
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  4 in total

1.  Predictive Value of the Texture Analysis of Enhanced Computed Tomographic Images for Preoperative Pancreatic Carcinoma Differentiation.

Authors:  Zhang Longlong; Li Xinxiang; Ge Yaqiong; Wei Wei
Journal:  Front Bioeng Biotechnol       Date:  2020-06-30

2.  Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy.

Authors:  Andreas Minh Luu; Orlin Belyaev; Philipp Höhn; Michael Praktiknjo; Monika Janot; Waldemar Uhl; Chris Braumann
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX.

Authors:  Philipp Höhn; Chris Braumann; Stefanie Nöpel-Dünnebacke; Johanna Munding; Waldemar Uhl; Andreas Minh Luu
Journal:  Visc Med       Date:  2020-07-31

4.  Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis.

Authors:  Rong Tang; Qingcai Meng; Wei Wang; Chen Liang; Jie Hua; Jin Xu; Xianjun Yu; Si Shi
Journal:  Gland Surg       Date:  2021-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.